Biomea Fusion (BMEA) Research & Development (2020 - 2026)
Biomea Fusion (BMEA) posted Research & Development of $9.1 million for Q1 2026, up 12.38% sequentially from $8.1 million in Q4 2025, and down 60.17% YoY from $22.9 million in Q1 2025.
Biomea Fusion (BMEA) Research & Development (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Research & Development for 7 years, with the latest figure at $9.1 million in Q1 2026.
- Quarterly Research & Development fell 60.17% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.2 million (down 55.04% YoY) and the FY2025 annual result came in at $62.0 million, down 47.51% from the prior year.
- Research & Development climbed to $9.1 million in Q1 2026 per BMEA's latest filing, from $8.1 million in the prior quarter.
- Over five years, Research & Development peaked at $33.8 million in Q1 2024 and troughed at $8.1 million in Q4 2025.
- A 5-year average of $20.8 million and a median of $21.9 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 198.84% in 2022, then plunged 67.85% in 2025.
- Over 5 years, Research & Development stood at $20.5 million in 2022, then jumped by 50.28% to $30.9 million in 2023, then slipped by 18.23% to $25.2 million in 2024, then slumped by 67.85% to $8.1 million in 2025, then rose by 12.38% to $9.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $9.1 million, $8.1 million, and $14.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | 9.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.14 Mn |
| Mar 31, 2026 | 9.12 Mn |
| Dec 31, 2025 | 8.12 Mn |
| Sep 30, 2025 | 14.40 Mn |
| Jun 30, 2025 | 16.57 Mn |
| Mar 31, 2025 | 22.90 Mn |
| Dec 31, 2024 | 25.24 Mn |
| Sep 30, 2024 | 27.24 Mn |
| Jun 30, 2024 | 31.83 Mn |
| Mar 31, 2024 | 33.78 Mn |
| Dec 31, 2023 | 30.87 Mn |
| Sep 30, 2023 | 25.35 Mn |
| Jun 30, 2023 | 21.94 Mn |
| Mar 31, 2023 | 24.40 Mn |
| Dec 31, 2022 | 20.54 Mn |
| Sep 30, 2022 | 18.24 Mn |
| Jun 30, 2022 | 12.58 Mn |
| Mar 31, 2022 | 11.35 Mn |
| Dec 31, 2021 | 11.09 Mn |
| Sep 30, 2021 | 7.89 Mn |